A detailed history of Jpmorgan Chase & CO transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 21,977 shares of PYXS stock, worth $43,734. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,977
Previous 21,312 3.12%
Holding current value
$43,734
Previous $70,000 14.29%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$2.83 - $3.94 $1,881 - $2,620
665 Added 3.12%
21,977 $80,000
Q2 2024

Aug 12, 2024

BUY
$3.06 - $5.58 $63,684 - $116,130
20,812 Added 4162.4%
21,312 $70,000
Q3 2023

Nov 14, 2023

SELL
$1.6 - $2.78 $6,100 - $10,600
-3,813 Reduced 88.41%
500 $0
Q2 2023

Aug 11, 2023

SELL
$2.46 - $4.07 $1,771 - $2,930
-720 Reduced 14.31%
4,313 $11,000
Q1 2023

May 11, 2023

BUY
$1.38 - $6.0 $6,945 - $30,198
5,033 New
5,033 $20,000
Q2 2022

Aug 11, 2022

SELL
$2.02 - $4.53 $10,071 - $22,586
-4,986 Closed
0 $0
Q1 2022

May 11, 2022

SELL
$4.04 - $11.43 $27,403 - $77,529
-6,783 Reduced 57.63%
4,986 $20,000
Q4 2021

Feb 10, 2022

BUY
$8.39 - $13.64 $98,741 - $160,529
11,769 New
11,769 $129,000

Others Institutions Holding PYXS

About Pyxis Oncology, Inc.


  • Ticker PYXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,096,400
  • Market Cap $69.8M
  • Description
  • Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...
More about PYXS
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.